Article: Cysteine-rich intestinal protein 2 (CRIP2) acts as a repressor of NF-κB-mediated proangiogenic cytokine transcription to suppress tumorigenesis and angiogenesis
| Title | Cysteine-rich intestinal protein 2 (CRIP2) acts as a repressor of NF-κB-mediated proangiogenic cytokine transcription to suppress tumorigenesis and angiogenesis | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Authors | Cheung, AKL3 Ko, JMY3 Lung, HL3 Chan, KW3 Stanbridge, EJ4 Zabarovsky, E1 5 Tokino, T2 Kashima, L2 Suzuki, T6 Kwong, DLW3 Chua, D3 Tsao, SW3 Lung, ML3 | ||||||||||||||||||
| Keywords | Antiangiogenesis Transcription regulator | ||||||||||||||||||
| Issue Date | 2011 | ||||||||||||||||||
| Publisher | National Academy of Sciences. The Journal's web site is located at http://www.pnas.org | ||||||||||||||||||
| Citation | Proceedings Of The National Academy Of Sciences Of The United States Of America, 2011, v. 108 n. 20, p. 8390-8395 [How to Cite?] DOI: http://dx.doi.org/10.1073/pnas.1101747108 | ||||||||||||||||||
| Abstract | Chromosome 14 was transferred into tumorigenic nasopharyngeal carcinoma and esophageal carcinoma cell lines by a microcell-mediated chromosome transfer approach. Functional complementation of defects present in the cancer cells suppressed tumor formation. A candidate tumor-suppressor gene, cysteine-rich intestinal protein 2 (CRIP2), located in the hot spot for chromosomal loss at 14q32.3, was identified as an important candidate gene capable of functionally suppressing tumor formation. Previous studies have shown that CRIP2 is associated with development. To date, no report has provided functional evidence supporting a role for CRIP2 in tumor development. The present study provides unequivocal evidence that CRIP2 can functionally suppress tumorigenesis. CRIP2 is significantly down-regulated in nasopharyngeal carcinoma cell lines and tumors. CRIP2 reexpression functionally suppresses in vivo tumorigenesis and angiogenesis; these effects are induced by its transcription-repressor capability. It interacts with the NF-κB/p65 to inhibit its DNA-binding ability to the promoter regions of the major proangiogenesis cytokines critical for tumor progression, including IL6, IL8, and VEGF. In conclusion, we provide compelling evidence that CRIP2 acts as a transcription repressor of the NF-κB-mediated proangiogenic cytokine expression and thus functionally inhibits tumor formation and angiogenesis. | ||||||||||||||||||
| ISSN | 0027-8424 2011 Impact Factor: 9.681 2011 SCImago Journal Rankings: 1.754 | ||||||||||||||||||
| DOI | http://dx.doi.org/10.1073/pnas.1101747108 | ||||||||||||||||||
| ISI Accession Number ID | WOS:000290719600063
Funding Information: This work was supported by the Research Grants Council and the University Grants Council of the Hong Kong Special Administrative Region, People's Republic of China (Grants 6615/07M and AoE/M-06/08, to M. L. L.); the University of Hong Kong Small Project Fund (Grant 200907176081, to A. K. L. C.); and the Swedish Cancer Society, Swedish Research Council, Swedish Institute, Royal Swedish Academy of Sciences, and Karolinska Institute (E.Z.). | ||||||||||||||||||
| PubMed Central ID | PMC3100921 | ||||||||||||||||||
| References | References in Scopus | ||||||||||||||||||
| Grants | Centre for Nasopharyngeal Carcinoma Research Functional investigation of candidate tumor suppressor gene, Protein tyrosine phosphatase receptor type G functional domains and angiogenesis effect. |
| dc.contributor.author | Cheung, AKL | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| dc.contributor.author | Ko, JMY | ||||||||||||||||||
| dc.contributor.author | Lung, HL | ||||||||||||||||||
| dc.contributor.author | Chan, KW | ||||||||||||||||||
| dc.contributor.author | Stanbridge, EJ | ||||||||||||||||||
| dc.contributor.author | Zabarovsky, E | ||||||||||||||||||
| dc.contributor.author | Tokino, T | ||||||||||||||||||
| dc.contributor.author | Kashima, L | ||||||||||||||||||
| dc.contributor.author | Suzuki, T | ||||||||||||||||||
| dc.contributor.author | Kwong, DLW | ||||||||||||||||||
| dc.contributor.author | Chua, D | ||||||||||||||||||
| dc.contributor.author | Tsao, SW | ||||||||||||||||||
| dc.contributor.author | Lung, ML | ||||||||||||||||||
| dc.date.accessioned | 2011-08-26T14:18:34Z | ||||||||||||||||||
| dc.date.available | 2011-08-26T14:18:34Z | ||||||||||||||||||
| dc.date.issued | 2011 | ||||||||||||||||||
| dc.description.abstract | Chromosome 14 was transferred into tumorigenic nasopharyngeal carcinoma and esophageal carcinoma cell lines by a microcell-mediated chromosome transfer approach. Functional complementation of defects present in the cancer cells suppressed tumor formation. A candidate tumor-suppressor gene, cysteine-rich intestinal protein 2 (CRIP2), located in the hot spot for chromosomal loss at 14q32.3, was identified as an important candidate gene capable of functionally suppressing tumor formation. Previous studies have shown that CRIP2 is associated with development. To date, no report has provided functional evidence supporting a role for CRIP2 in tumor development. The present study provides unequivocal evidence that CRIP2 can functionally suppress tumorigenesis. CRIP2 is significantly down-regulated in nasopharyngeal carcinoma cell lines and tumors. CRIP2 reexpression functionally suppresses in vivo tumorigenesis and angiogenesis; these effects are induced by its transcription-repressor capability. It interacts with the NF-κB/p65 to inhibit its DNA-binding ability to the promoter regions of the major proangiogenesis cytokines critical for tumor progression, including IL6, IL8, and VEGF. In conclusion, we provide compelling evidence that CRIP2 acts as a transcription repressor of the NF-κB-mediated proangiogenic cytokine expression and thus functionally inhibits tumor formation and angiogenesis. | ||||||||||||||||||
| dc.description.grant | Centre for Nasopharyngeal Carcinoma Research | ||||||||||||||||||
| dc.description.grant | Functional investigation of candidate tumor suppressor gene, Protein tyrosine phosphatase receptor type G functional domains and angiogenesis effect. | ||||||||||||||||||
| dc.description.grantcode | 101179 | ||||||||||||||||||
| dc.description.grantcode | 101349 | ||||||||||||||||||
| dc.description.nature | link_to_OA_fulltext | ||||||||||||||||||
| dc.identifier.citation | Proceedings Of The National Academy Of Sciences Of The United States Of America, 2011, v. 108 n. 20, p. 8390-8395 [How to Cite?] DOI: http://dx.doi.org/10.1073/pnas.1101747108 | ||||||||||||||||||
| dc.identifier.doi | http://dx.doi.org/10.1073/pnas.1101747108 | ||||||||||||||||||
| dc.identifier.epage | 8395 | ||||||||||||||||||
| dc.identifier.hkuros | 190806 | ||||||||||||||||||
| dc.identifier.isi | WOS:000290719600063
Funding Information: This work was supported by the Research Grants Council and the University Grants Council of the Hong Kong Special Administrative Region, People's Republic of China (Grants 6615/07M and AoE/M-06/08, to M. L. L.); the University of Hong Kong Small Project Fund (Grant 200907176081, to A. K. L. C.); and the Swedish Cancer Society, Swedish Research Council, Swedish Institute, Royal Swedish Academy of Sciences, and Karolinska Institute (E.Z.). | ||||||||||||||||||
| dc.identifier.issn | 0027-8424 2011 Impact Factor: 9.681 2011 SCImago Journal Rankings: 1.754 | ||||||||||||||||||
| dc.identifier.issue | 20 | ||||||||||||||||||
| dc.identifier.pmcid | PMC3100921 | ||||||||||||||||||
| dc.identifier.pmid | 21540330 | ||||||||||||||||||
| dc.identifier.scopus | eid_2-s2.0-79957787635 | ||||||||||||||||||
| dc.identifier.spage | 8390 | ||||||||||||||||||
| dc.identifier.uri | http://hdl.handle.net/10722/137193 | ||||||||||||||||||
| dc.identifier.volume | 108 | ||||||||||||||||||
| dc.language | eng | ||||||||||||||||||
| dc.publisher | National Academy of Sciences. The Journal's web site is located at http://www.pnas.org | ||||||||||||||||||
| dc.publisher.place | United States | ||||||||||||||||||
| dc.relation.ispartof | Proceedings of the National Academy of Sciences of the United States of America | ||||||||||||||||||
| dc.relation.references | References in Scopus | ||||||||||||||||||
| dc.subject.mesh | Adaptor Proteins, Signal Transducing - physiology | ||||||||||||||||||
| dc.subject.mesh | Cell Transformation, Neoplastic - genetics | ||||||||||||||||||
| dc.subject.mesh | Cytokines - genetics - physiology | ||||||||||||||||||
| dc.subject.mesh | NF-kappa B - metabolism | ||||||||||||||||||
| dc.subject.mesh | Neovascularization, Pathologic - genetics | ||||||||||||||||||
| dc.subject | Antiangiogenesis | ||||||||||||||||||
| dc.subject | Transcription regulator | ||||||||||||||||||
| dc.title | Cysteine-rich intestinal protein 2 (CRIP2) acts as a repressor of NF-κB-mediated proangiogenic cytokine transcription to suppress tumorigenesis and angiogenesis | ||||||||||||||||||
| dc.type | Article |
- Karolinska University Hospital
- Sapporo Medical University
- The University of Hong Kong
- UC Irvine
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
- Hokkaido University

